Haemodynamic Effects of Sodium–Glucose Cotransporter 2 Inhibitor Treatment in Chronic Heart Failure Patients
Sodium–glucose cotransporter 2 inhibitors (SGLT-2i) are now recommended in the current European Society of Cardiology/American College of Cardiology guidelines for the treatment of heart failure (HF) across the spectrum of left ventricular ejection fraction (LVEF) and several large trials have docum...
Saved in:
| Main Authors: | C Noah Nilsson, Mads Kristian Ersbøll, Finn Gustafsson |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Radcliffe Medical Media
2024-09-01
|
| Series: | Cardiac Failure Review |
| Online Access: | https://www.cfrjournal.com/articleindex/cfr.2023.25 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Treatment of Heart Failure with Sodium-glucose Cotransporter Type 2 Inhibitors
by: Riber Fabián Donoso Noroña, et al.
Published: (2024-09-01) -
The role of sodium – glucose cotransporter-2 inhibitors in the treatment of different phenotypes of chronic heart failure
by: M. Yu. Kolesnyk, et al.
Published: (2024-03-01) -
Antifibrotic effects of sodium-glucose cotransporter 2 inhibitors in patients with heart failure
by: Yu. S. Ignatova, et al.
Published: (2024-02-01) -
Timing and Adherence Matter for Sodium–Glucose Cotransporter‐2 Inhibitors in Heart Failure
by: Mehmet Birhan Yilmaz, et al.
Published: (2025-04-01) -
Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Heart Failure: An Update
by: Nicia I. Profili, et al.
Published: (2024-10-01)